• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$3.33 -$0.10 (-2.92%)

REAL-TIME: Last trade at

Orexigen Therapeutics, Inc.

NASDAQ:OREX

Jump to this page for:

Related Resources

Orexigen® Therapeutics To Be Added to the NASDAQ Biotechnology Index

5/14/2012 by PR Newswire

Mulling Arena Pharma's Future With Obesity Drug on Approval Path

5/14/2012 by TheStreet.com

Arena and Orexigen Compete to Bring First Weight Loss Drug to Market in Nearly 13 Years

5/14/2012 by StockWatch

Arena and Orexigen Compete to Bring First Weight Loss Drug to Market in Nearly 13 Years

5/14/2012 by Marketwire

NASDAQ Changes Up Biotech Index Members & Weightings

5/14/2012 by 24/7 Wall Street

24/7 Wall St. Closing Bell

5/11/2012 by 24/7 Wall Street

Jefferies Upgrades Arena Pharmaceuticals to 'Buy'

5/11/2012 by CNBC Video

Arena Soars After Weight-Loss Pill Recommended for Approval by FDA Staff

5/11/2012 by Bloomberg.com

Orexigen rallies 10% to $3.70 after FDA panel backs Arena drug

5/10/2012 by Theflyonthewall.com

Company news: Pfizer, Orexigen

5/10/2012 by Medical Marketing & Media (MM&M)

Battle to Fight Obesity

5/10/2012 by CNBC Video

Orexigen reports Q1 EPS (16c), consensus (12c)

5/9/2012 by Theflyonthewall.com

Orexigen Therapeutics, Inc. (OREX) Misses Q1 EPS by 4c

5/9/2012 by StreetInsider.com

Orexigen® Therapeutics Reports First Quarter Ended March 31, 2012 Financial Results

5/9/2012 by PR Newswire

Catalysts Move Drug and Medtech Stocks: Michael Hay and Jocelyn August

5/3/2012 by NASDAQ

Conditions of Growth, Economic Analysis - Research Report on Orexigen Therapeutics, Inc. and AVEO Pharmaceuticals, Inc.

5/1/2012 by Marketwire

Orexigen® Therapeutics Schedules May 9, 2012 Webcast Discussion of Financial Results for the First Quarter Ended March 31, 2012

5/1/2012 by PR Newswire

Lota S. Zoth Joins Orexigen Therapeutics Board of Directors

4/27/2012 by StockWatch

Lota S. Zoth Joins Orexigen Therapeutics Board of Directors

4/27/2012 by PR Newswire

Arena Shares Sink as Big Dates for Diet Pill Makers Near

4/17/2012 by Minyanville

Zacks' Voice of the People Highlights Opportunities with Starbucks, Realty Income, Keryx Biopharma, Bon-Ton Stores and Orexigen Therapeutics

4/12/2012 by PR Newswire

Zacks' Voice of the People highlights opportunities with Starbucks, Realty Income, Keryx Biopharma, Bon-Ton Stores and Orexigen Therapeutics - Press Releases

4/12/2012 by Zacks Investment Research

BofA/Merrill's biotech and European pharma analysts hold a conference call

4/11/2012 by Theflyonthewall.com

VIVUS Faces Shareholder Risks After FDA Delay On Obesity Pill (VVUS, ARNA, OREX)

4/10/2012 by 24/7 Wall Street

Top FDA Approval Decision Gurus Weigh in on Vivus' Obesity Drug

4/10/2012 by TheStreet.com

Orexigen management to meet with JPMorgan

4/9/2012 by Theflyonthewall.com

Orexigen management to meet with JMP Securities

4/3/2012 by Theflyonthewall.com

3 Anti-Obesity Drug Companies Poised To Grow

4/3/2012 by Seeking Alpha

FDA Advisors Back Heart Studies for Obesity Drugs

3/30/2012 by NewsInferno

FDA panel votes that obesity drug makers should study heart risk, Bloomberg says

3/29/2012 by Theflyonthewall.com

UPDATE: VIVUS (VVUS) Shares Spike 9+%, Orexigen (OREX) Shares Move Lower

3/29/2012 by StreetInsider.com

VIVUS drug's CV profile viewed positively by FDA, says Rodman & Renshaw

3/29/2012 by Theflyonthewall.com

VIVUS, Inc. and Orexigen Therapeutics, Inc. Await FDA Approval for Weight Loss Drugs

3/29/2012 by StockWatch

VIVUS, Inc. and Orexigen Therapeutics, Inc. Await FDA Approval for Weight Loss Drugs

3/29/2012 by Marketwire

FDA May Require Heart Studies for New Obesity Drugs

3/27/2012 by NewsInferno

Leerink Swann Says Orexigen (OREX) is Still the Best Play After Obesity Drug CV Study Briefing Documents, Boosts Target (VVUS)

3/26/2012 by StreetInsider.com

Orexigen remains best play in obesity after briefing documents, says Leerink

3/26/2012 by Theflyonthewall.com

Nutrisystem Still Searching For Sustainability (NTRI, WTW, MED, VVUS)

3/12/2012 by Investopedia

Orexigen remains a top small-cap biotech pick at Leerink

3/9/2012 by Theflyonthewall.com

Orexigen Loss Shrinks in Q4

3/9/2012 by Drug Discovery & Development
See More Articles...